Catalent expands Kansas City plant for Pharmacyclics commercial contract

By Dan Stanton

- Last updated on GMT

Catalent awarded commercial contract from KC, Missouri facility
Catalent awarded commercial contract from KC, Missouri facility
Catalent says it is creating dedicated space and possibly jobs at its Missouri facility in order to service a commercial contract for Pharmacyclics’ oncology drug Imbruvica.

The contract development and manufacturing organisation (CDMO) has manufactured clinical supplies of Imbruvica (Ibrutinib)on behalf of Pharmacyclics for more than three years, a company spokesman told, and following approval from the US Food and Drug Administration (FDA) earlier this month, Catalent will now provide drug product capsules for commercial supply.

The drug is manufactured from Catalent’s Kansas City, Missouri, facility acquired in 2011 from Aptuit​ and we were told as part of continued global investment the site will see the firm “building out dedicated space to accommodate the commercial volume” ​from this extended partnership.

“[Kansas City] provides a wide range of fully integrated support services from formulation development and analytical testing to clinical supply services as well as clinical and commercial manufacturing for oral dose forms,”​ we were told and “the expansion is scheduled to be completed by the middle of 2014, and Catalent will announce further details in the near future.”

The agreement was reached after the 450,000 q ft site underwent an FDA Pre-Approval Inspection that resulted in zero observations, the company said.

In a statement Heow Tan, Chief of Technical Operations at Pharmacyclics, said: “It is important that we work with a development partner with expertise in both clinical and commercial supply as well as US and worldwide GMP regulations, to ensure reliable quality supply to patients.”


“Catalent currently employs 334 workers in Kansas City,”​ was told, “and it is likely that we will increase the number of employees to accommodate this and other recently announced programmes at the site.”

Furthermore, the site has been strengthened by two other partnerships reaching regulatory approval announced in the last year. In December 2012 Exelixis’ Cometriq (cabozantinib) gained FDA approval, and a month later Aegerion’s Juxtapid (lomitapide) also got the thumbs up (and subsequently European Commission approval).

Related news

Show more

Related products


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers